News Archive
27 August
2009
Clavis Pharma ASA receives USD 1.1 million Grant from Innovation Norway
Clavis Pharma ASA receives USD 1.1 million Grant from Innovation Norway to Accelerate the Phase II Programme of Intravenous CP-4126 in Pancreatic Cancer
Clavis Pharma ASA receives USD 1.1 million Grant from Innovation Norway
Clavis Pharma ASA receives USD 1.1 million Grant from Innovation Norway to Accelerate the Phase II Programme of Intravenous CP-4126 in Pancreatic Cancer
18 August 2009
Clavis Pharma announces Successful Completion of Share Offering
Clavis Pharma ASA (OSE:CLAVIS) today announced the successful completion of the subsequent share offering, following the private placement in June that raised NOK 129 million in gross proceeds. The subsequent offering of 650,000 shares, each with a par value of NOK 1.00, at subscription price of NOK 12.00 per share, was oversubscribed by approximately 100 percent, and resulted in gross proceeds of NOK 7.8 million.
Clavis Pharma announces Successful Completion of Share Offering
Clavis Pharma ASA (OSE:CLAVIS) today announced the successful completion of the subsequent share offering, following the private placement in June that raised NOK 129 million in gross proceeds. The subsequent offering of 650,000 shares, each with a par value of NOK 1.00, at subscription price of NOK 12.00 per share, was oversubscribed by approximately 100 percent, and resulted in gross proceeds of NOK 7.8 million.
15 July 2009
Clavis Pharma's NOK 129 million Private Placement approved at Extraordinary General Meeting
Oslo, Norway, 15 July 2009. Clavis Pharma ASA (OSE: CLAVIS) announces that all items proposed to shareholders at its Extraordinary General Meeting held today in Oslo were resolved according the Board's proposal.
Clavis Pharma's NOK 129 million Private Placement approved at Extraordinary General Meeting
Oslo, Norway, 15 July 2009. Clavis Pharma ASA (OSE: CLAVIS) announces that all items proposed to shareholders at its Extraordinary General Meeting held today in Oslo were resolved according the Board's proposal.
3 July 2009
Clavis Pharma announces successful Investigational New Drug application (IND) review for Intravenous CP-4126
Clavis Pharma ASA (OSE: CLAVIS) announces today that it has received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its phase II clinical programme for Intravenous CP-4126. Intravenous CP-4126 is in development as a new, first-line treatment for pancreatic cancer and the phase II program has already been initiated in Europe. Clavis Pharma will now begin preparations at selected clinical sites for an expansion of the phase II programme into the USA.
Clavis Pharma announces successful Investigational New Drug application (IND) review for Intravenous CP-4126
Clavis Pharma ASA (OSE: CLAVIS) announces today that it has received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its phase II clinical programme for Intravenous CP-4126. Intravenous CP-4126 is in development as a new, first-line treatment for pancreatic cancer and the phase II program has already been initiated in Europe. Clavis Pharma will now begin preparations at selected clinical sites for an expansion of the phase II programme into the USA.
Notice
of Extraordinary General Meeting
in Clavis Pharma ASA on 15 July 2009 at 15:00 CET at Parkveien 55, Oslo, Norway
in Clavis Pharma ASA on 15 July 2009 at 15:00 CET at Parkveien 55, Oslo, Norway
26 June 2009
Clavis Pharma raises NOK 129 million (USD 20 million) in a private placement to fund further development of its pipeline of novel anticancer drug candidates
Clavis Pharma ASA (OSE: CLAVIS) today announced that the Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share (the "Private Placement").
Clavis Pharma raises NOK 129 million (USD 20 million) in a private placement to fund further development of its pipeline of novel anticancer drug candidates
Clavis Pharma ASA (OSE: CLAVIS) today announced that the Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share (the "Private Placement").
17 June 2009
Phase II trial demonstrates elacytarabine may increase survival threefold in patients with late-stage leukaemia
New investigational drug also shown to improve remission rates and reduce short-term mortality compared to previous treatments. Clavis Pharma ASA (OSE: CLAVIS) today announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML).
Phase II trial demonstrates elacytarabine may increase survival threefold in patients with late-stage leukaemia
New investigational drug also shown to improve remission rates and reduce short-term mortality compared to previous treatments. Clavis Pharma ASA (OSE: CLAVIS) today announces positive final results from a Phase II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML).
29 May 2009
Clavis Pharma to present positive clinical data from elacytarabine and intravenous CP-4126 at ASCO 2009
Clavis Pharma ASA (OSE: CLAVIS) announces that positive clinical data from its two lead development products will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009 in Orlando, Florida.
Clavis Pharma to present positive clinical data from elacytarabine and intravenous CP-4126 at ASCO 2009
Clavis Pharma ASA (OSE: CLAVIS) announces that positive clinical data from its two lead development products will be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 29 to June 2, 2009 in Orlando, Florida.
15 May 2009
Minutes from Annual General Meeting 2009
The Annual General Meeting of Clavis Pharma ASA was held on 14 May 2009 in Parkveien 55, Oslo. Please find the minutes of the Annual General Meeting attached.
Minutes from Annual General Meeting 2009
The Annual General Meeting of Clavis Pharma ASA was held on 14 May 2009 in Parkveien 55, Oslo. Please find the minutes of the Annual General Meeting attached.
6 May 2009
Positive preclinical data for fourth drug candidate - CP-4200
Clavis Pharma ASA (OSE: CLAVIS) announced today pre-clinical data that differentiate CP-4200 from current standard therapy. CP-4200, Clavis Pharma's fourth drug candidate, represents a new family of Lipid Vector Technology (LVT) drugs called epigenetic modulators for the treatment of solid tumours and haematological malignancies. Epigenetic modulators are expected to constitute an important drug class of future cancer therapy.
Positive preclinical data for fourth drug candidate - CP-4200
Clavis Pharma ASA (OSE: CLAVIS) announced today pre-clinical data that differentiate CP-4200 from current standard therapy. CP-4200, Clavis Pharma's fourth drug candidate, represents a new family of Lipid Vector Technology (LVT) drugs called epigenetic modulators for the treatment of solid tumours and haematological malignancies. Epigenetic modulators are expected to constitute an important drug class of future cancer therapy.